|
|||||
|
|
| 普乐可复在肾移植中的临床应用探讨 | |
| 引用本文： | 陈恺杰,唐群业. 普乐可复在肾移植中的临床应用探讨[J]. 河北医学, 2005, 11(7): 626-628 |
| 作者姓名： | 陈恺杰 唐群业 |
| 作者单位： | 广东医学院附属医院,广东,湛江,524001;上海复旦大学附属中山医院,上海,200032 |
| 摘 要： | 目的:评价普乐可复(FK506)对肾移植患者免疫抑制作用的疗效和安全性。方法:将70例肾移植患者分为两组。普乐可复组(n=35):主要用药为普乐可复+硫唑嘌呤(Aza)+泼尼松(Pred);环孢素A(CsA)组(n=35):主要用药为CsA+Aza+Pred。结果:观察6个月,普乐可复组急性排斥发生率为0,而CsA组有9例(25.7%)发生急性排斥反应(P<0.05);普乐可复组的肝毒性和神经毒性反应发生率均比CsA组低(P<0.05);普乐可复组有3例(8.6%)发生高血糖反应(P>0.05)。结论:普乐可复在肾移植中排斥发生率低,毒副作用小,是一种安全高效的新型免疫抑制剂。 |
| 关 键 词： | 普乐可复 环孢素A 肾移植 |
| 文章编号： | 1006-6233(2005)07-0626-03 |
Clinical Application of FK506 in Renal Transplantation |
|
| CHEN Kai-jie,et al. Clinical Application of FK506 in Renal Transplantation[J]. Hebei Medicine, 2005, 11(7): 626-628 | |
| Authors: | CHEN Kai-jie et al |
| Abstract: | Objective: To investigate the immunosuppressive efficacy and safety of FK506 on renal transplant recipients. Method: 70 cases of renal transplant recipients were divided into two groups: FK506 group was treated with FK506+Aza+Pred, CsA group was treated with CsA+Aza+Pred. Result: After six months' observation, there is no acute rejection in FK506 group while 9 patients in CsA group(25.7%) presented acute rejection(P<0.05). Incidence of hepatotoxicity and neurotoxicity in FK506 group was lower than that of CsA group(P<0.05). 3 cases in FK506 group presented high blood glucose (8.6%)(P>0.05). Conclusion: FK506 is a new effective and safe immunity inhibitor in kidney transplant. |
| Keywords: | FK506 CsA Kidney transplant |
| 本文献已被 CNKI 万方数据 等数据库收录！ | |